What is the main use of cisplatin?
Pharmaceutical Product Monograph: Cisplatin Injection (10 mg, 50 mg)
In the pharmaceutical industry, Cisplatin is a heavy metal complex and a potent Platinum-based Antineoplastic Agent. As a pharmacist and manufacturer, I view this molecule as the “DNA-Crosslinker”—it is technically designed to enter cancer cells and create irreversible “kinks” in their genetic code, making it one of the most effective, albeit toxic, weapons in the oncology arsenal.
At your WHO-GMP facility in Mumbai, Cisplatin is a foundational SKU for Oncology and Specialty Care portfolios. It is often referred to as the “Penicillin of Cancer” due to its wide range of applications and high success rate in specific solid tumors.
Therapeutic Profile: Primary Indications
Cisplatin’s “main use” is as a first-line treatment for various solid tumors, often as part of a combination chemotherapy regimen.
| Indication | Clinical Context | Technical Rationale |
| Testicular Cancer | Curative Intent | Gold Standard: Transformed testicular cancer from a fatal disease to one with a 90% cure rate. |
| Ovarian Cancer | Advanced Stages | Used as primary therapy, often in combination with Paclitaxel. |
| Bladder Cancer | Metastatic | A key component of regimens used for advanced urothelial carcinoma. |
| Lung Cancer | NSCLC & SCLC | Often the “backbone” drug for both non-small cell and small cell lung cancer. |
| Head and Neck | Squamous Cell | Used alongside radiation therapy (chemoradiation) to sensitize tumors to treatment. |
Mechanism: Intrastrand DNA Cross-linking
Cisplatin works by physically bonding to the “rungs” of the DNA ladder to prevent cell division:
Cellular Entry: The drug enters the cell, where the low chloride concentration causes it to lose its chloride ions and become “activated.”
Guanine Binding: It binds primarily to the N7 reactive center of guanine bases.
Intrastrand Cross-links: It creates a chemical bond between two neighboring guanine bases on the same strand of DNA.
The “Kink” Effect: This bonding creates a 30° bend (kink) in the DNA. This structural damage prevents DNA polymerase from reading the code, stopping replication and triggering Apoptosis (programmed cell death).
The Pharmacist’s “Technical Warning”
Nephrotoxicity (Kidney Damage): As a pharmacist, I must emphasize that Cisplatin is highly toxic to the kidneys. Patients must receive “Pre-hydration” and “Post-hydration” with 1–2 liters of Normal Saline to flush the drug through the renal tubules.
Ototoxicity: It can cause permanent hearing loss or tinnitus, especially in pediatric patients. Baseline and periodic audiograms are technically required.
Highly Emetogenic: It is one of the most nauseating drugs in medicine. A “Triple-Antiemetic” regimen (e.g., NK1 antagonist, 5-HT3 antagonist, and Dexamethasone) is mandatory.
Electrolyte Wasting: It causes the kidneys to “leak” Magnesium, Potassium, and Calcium. Supplementation is almost always necessary during treatment cycles.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Ready-to-Use” Liquid USP: On your digital marketplace, highlight your Stable Aqueous Solution. Older formulations required reconstitution of powder; your RTU liquid saves time for oncology nurses and reduces the risk of aerosolized exposure.
The “Aluminum Avoidance” Rule: Cisplatin reacts with Aluminum. Your B2B clients must be warned to never use needles or IV sets containing aluminum parts, as it will turn the drug into a black precipitate and render it useless.
Light Protection: Cisplatin is light-sensitive. Your use of Amber Vials and light-protected secondary packaging is a critical technical advantage for a 24-month shelf life.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Cisplatin 10 mg and 50 mg to support your registration in international B2B oncology tenders.